Site Sponsors
  • Oxford Instruments Nanoanalysis - X-Max Large Area Analytical EDS SDD
  • Strem Chemicals - Nanomaterials for R&D
  • Park Systems - Manufacturer of a complete range of AFM solutions
Posted in | Nanoanalysis | Nanobusiness

Henderson Morley Selects Nanosight Nanoparticle Tracking Analysis to Quantify Virus Particle Number for Batch to Batch Control

Published on September 1, 2009 at 6:38 AM

NanoSight, manufacturers of unique nanoparticle characterization technology, announce that UK biotechnology company, Henderson Morley plc, is using nanoparticle tracking analysis (NTA) to quantify virus particle number for batch to batch control.

Dr Chris Hartley, Principal Scientist at Henderson Morley

Henderson Morley is developing an exciting pipeline of anti-viral drugs and vaccines and biological products to fight a wide range of diseases in humans and animals. Their lead vaccine technology platform uses PREPS and L-particles which are virus-like particles derived from Human Herpes Virus 1 (HHV-1). These particles have the same size as herpes viruses, but do not contain viral DNA and are therefore sterile. Conventional viral quantification relies on the infectious yield of viruses but as these particles do not replicate, an alternate quantification technique had to be found.

Previously the only way to quantify particle number relied on less accurate protein concentration measurements. The company had also used costly and time consuming electron microscopy through a local university, and although this gave good results, it was not practical for batch to batch quantification of the L and PREPS particles.

Several benefits have been produced since the purchase the NanoSight system. Henderson Morley’s Principal Scientist, Dr Chris Hartley, has been impressed with the speed and ease of use. “The reproducibility of results providing both particle size and particle counts in real time has been excellent. Also negligible on-going and running costs have meant that the NanoSight instrument is proving to be a very cost effective solution.”

NanoSight’s Head of Applications Science, Andrew Malloy, adds “It is clear that we have a solution to a widespread problem, that of assessing viral titre. The results we are delivering for a range of users in viral vaccine production are contributing directly to improving the yield and stability of their products throughout the production process. We are delighted that Henderson Morley were so quick to recognise the value these analyses can provide.”

To learn more about viruses and their characterization using NTA, please visit www.nanosight.com. Register for the latest issue of NanoTrail, the company’s eNewsletter.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Submit